Special notice: For important updates about COVID-19 and its impact on CNSI facilities, please visit our Coronavirus guidance page.
Molecular Screening Shared Resource
Delivering High Throughput Screening to the UCLA research community
The MSSR is a core facility open to all research labs on campus.
The services provided include the use of high throughput screening (HTS) technology, a total of roughly 200,000 compounds in various libraries, siRNA sets of the druggable genome for mouse and human and a database of results from screens. Please use the links above to find out more about the MSSR.
The MSSR is currently funded by the JCCC, the Department of Molecular and Medical Pharmacology, the Department of Microbiology, Immunology and Molecular Genetics, and the Dean’s office, David Geffen School of Medicine and the California NanoSystems Institute.
Contact Information:
Robert Damoiseaux, Director
Phone: (310) 794-1974
Email: rdamoiseaux@mednet.ucla.edu
Scientific Advisors
Owen Witte, MD
Jing Huang, PhD
The MSSR is located at 2145 California (N)anoSystems Institute (CNSI).
- High-Throughput-Screening
- Drug Discovery
- Functional Genomics & Novel Applications
- User base includes: Small BioTech, Big Pharma, Academics, NIH
- Chemical Libraries: 180,000 compounds of drug-like molecules with emphasis on desirable target classes such as kinases, proteases, phosphatases, GPCRs and ion channel
- cDNA overexpression library of 16,000 clones accessible as "expression-ready" sets
- Plater reader based readouts and high content screening
Featured News
September 11, 2019 | UCLA-led research reveals potential treatments for deadly tropical disease
September 11, 2019 | UCLA-led research reveals potential treatments for deadly tropical disease One medicine is already FDA-approved for other uses, the second is a new synthetic antibiotic. by Wayne Lewis Philip Bulterys and colleagues tested more than 220,000...
February 25, 2019 | Lab-grown mini tumors could help identify personalized treatments for people with rare cancers
UCLA scientists have developed a new method to quickly screen hundreds of drugs in order to identify treatments that can target specific tumors. February 25, 2019 | Lab-grown mini tumors could help identify personalized treatments for people with rare cancers New...
September 3, 2018 | 8,000 new antibiotic combinations are surprisingly effective, UCLA biologists report
Scientists have traditionally believed that combining more than two drugs to fight harmful bacteria would yield diminishing returns. The prevailing theory is that that the incremental benefits of combining three or more drugs would be too small to matter, or that the...
February 8, 2018 | Device that measures cell strength could help identify drugs for asthma, hypertension and muscular dystrophy
Engineers, doctors and scientists at UCLA and Rutgers University have developed a tool that measures the physical strength of individual cells 100 times faster than current technologies.February 8, 2018 | Device that measures cell strength could help identify drugs...
UC launches drug discovery consortium
The UC Drug Discovery Consortium aims to support early drug discovery projects on UC campuses by sharing resources and expertise. The consortium launched with the help of a UC grant to the Drug, Device, Discovery and Development workgroup of UC Biomedical Research...
Using gene-editing technology for faster, cheaper antiviral drug development
In an advance that could lead to the development of better treatments for viral pathogens, such as Zika, a team of scientists at the California NanoSystems Institute at UCLA are developing a more accurate and more cost-effective DNA-screening system based on...